Pembrolizumab Shows Early Triple-Negative Breast Cancer Potential
Use of neoadjuvant pembrolizumab with chemotherapy increases the likelihood of a pathological complete response in women with early-stage triple-negative breast cancer...
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Use of neoadjuvant pembrolizumab with chemotherapy increases the likelihood of a pathological complete response in women with early-stage triple-negative breast cancer...
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.